Osteonecrosis of the jaw and bisphosphonates in cancer: A narrative review

Nature Reviews Endocrinology

Volumn 7, Issue 1, 2011, Pages 34-42

  Migliorati, Cesar A ^a   Epstein, Joel B ^b   Abt, Elliot ^c   Berenson, James R ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^d INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; MEDRONATE TECHNETIUM TC 99M; NITROGEN; PAMIDRONIC ACID; TETRACYCLINE; THALIDOMIDE; ZOLEDRONIC ACID;

ANTIBIOTIC THERAPY; AVASCULAR NECROSIS; BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DEBRIDEMENT; DIABETES MELLITUS; DRUG WITHDRAWAL; ERBIUM YAG LASER; GENETIC SUSCEPTIBILITY; HUMAN; HYPERBARIC OXYGEN; JAW OSTEONECROSIS; MULTIPLE MYELOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; TOOTH DISEASE; TOOTH RADIOGRAPHY; TREATMENT OUTCOME; WOUND HEALING;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; NEOPLASMS; OSTEONECROSIS; OSTEOPOROSIS;

EID: 78650307647     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.195     Document Type: Review

References (121)

1. Cosman, F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr. Pract. 15, 483-493 (2009).
2. Bilezikian, J. P efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am. J. Med. 122 (Suppl.), S14-S21 (2009).
3. Berenson, J. R., Rajdev, L. & Broder, M. Treatment strategies for skeletal complications of cancer. Cancer Biol. Ther. 5, 1074-1077 (2006).
4. Body, J. J. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin. Cancer Res. 12, 6258s-6263s (2006).
5. Body, J. J. et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur. J. Cancer 43, 852-858 (2007).
6. Arum, S. M. New developments surrounding the safety of bisphosphonates. Curr. Opin. Endocrinol. Diabetes Obes. 15, 508-513 (2008).
7. Diel, I. J., Bergner, R. & Grötz, K. A. Adverse effects of bisphosphonates: current issues. J. Support Oncol. 5, 475-482 (2007).
8. Ing-Lorenzini, K. et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 32, 775-785 (2009).
9. Capeci, C M. & Tejwani, N. C Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J. Bone Joint Surg. Am. 91, 2556-2561 (2009)
10. King, A. E. & Umland, E. M. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28, 667-677 (2008).
11. Migliorati, C A., Siegel, M. A. & Elting, L. S. Bisphosphonate- associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 7, 508-514 (2006).
12. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\2009 update. J. Oral Maxillofac. Surg. 67 (Suppl.), 2-12 (2009).
13. Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J. Oral Maxillofac. Surg. 61, 1115-1117 (2003).
14. Migliorati, C A. Bisphosphanates and oral cavity avascular bone necrosis. J. Clin. Oncol. 21, 4253-4254 (2003).
15. Migliorati, C A., Schubert, M. M., Peterson, D. E. & Seneda, L. M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104, 83-93 (2005).
16. Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J. & Engroff, S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62, 527-534 (2004).
17. Lazarovici, T. S. et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J. Oral Maxillofac. Surg. 67, 850-855 (2009).
18. Junquera, L., Gallego, L., Cuesta, P, Pelaz, A. & de vicente, J. C Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. Am. J. Otolaryngol. 30, 390-395 (2009).
19. Favia, G., Pilolli, G. P & Maiorano, E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J. Rheumatol. 36, 2780-2787 (2009).
20. Magopoulos, C et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am. J. Otolaryngol. 28, 158-163 (2007)
21. Thumbigere-Math, V. et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J. Oral Maxillofac. Surg. 67, 1904-1913 (2009).
22. Hong, J. W. et al. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos. Int 21, 847-853 (2009).
23. Saussez, S. et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 119, 323-329 (2009).
24. Pozzi, S. et al. Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. Am. J. Hematol. 84, 850-852 (2009).
25. Kos, M., Kuebler, J. F., Luczak, K. & Engelke, W. Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk. J. Craniomaxillofac. Surg. 38, 255-259 (2009).
26. Woo, S. B., Hellstein, J. W. & Kalmar, J. R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144, 753-761 (2006).
27. Lipton, A. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88, 1082-1090 (2000).
28. Berenson, J. R. et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 16, 593-602 (1998).
29. Rosen, L. S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7, 377-387 (2001).
30. Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98, 1735-1744 (2003).
31. Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100, 2613-2621 (2004).
32. Saad, F. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst 96, 879-882 (2004). (Pubitemid 38807610)
33. Coleman, R. E. Risks and benefits of bisphosphonates. Br. J. Cancer 98, 1736-1740 (2008).
34. Kyle, R. A. et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 25, 2464-2472 (2007).
35. Terpos, E., Berenson, J., Cook, R. J., Lipton, A. & Coleman, R. E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24, 1043-1049 (2010).
36. Green, J. R. Antitumor effects of bisphosphonates. Cancer 97 (Suppl.), 840-847 (2003).
37. Morgan, G. et al. evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study. J. Clin. Oncol. (Meeting Abstracts) 28, 8021 (2010).
38. Gnant, M. et al. endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
39. Ripamonti, C I. et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20, 137-145 (2009).
40. Black, D. M. et al. effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term extension (FLeX): a randomized trial. JAMA 296, 2927-2938 (2006).
41. Bone, H. G. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189-1199 (2004).
42. ClinicalTrials.gov Zoledronic acid treatment (every 4 or 12 weeks) to prevent skeletal complications in advanced multiple myeloma patients (Z-MARK) [online], http://clinicaltrials.gov/ct2/show/NCT0 0622505?term= NCT00622505&rank=1 (2010).
43. McMahon, R. E. et al. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J. Oral Maxillofac. Surg. 65, 1899-1900 (2007).
44. Khosla, S. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22, 1479-1491 (2007).
45. Mawardi, H. et al. Sinus tracts\an early sign of bisphosphonate- associated osteonecrosis of the jaws? J. Oral Maxillofac. Surg. 67, 593-601 (2009).
46. Wilde, F et al. Positron-emission tomography maging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107, 412-419 (2009).
47. Krishnan, A., Arslanoglu, A., Yildirm, N., Silbergleit, R. & Aygun, N. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance maging findings. J. Comput Assist. Tomogr. 33, 298-304 (2009).
48. O'Ryan, F S. et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J. Oral Maxillofac. Surg. 67, 1363-1372 (2009).
49. Dore, F et al. Bone scintigraphy and SPeCT/CT of bisphosphonate-induced osteonecrosis of the jaw. J. Nucl. Med. 50, 30-35 (2009).
50. Arce, K., Assael, L. A., Weissman, J. L. & Markiewicz, M. R. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J. Oral Maxillofac Surg. 67 (Suppl.), 75-84 (2009).
51. Morag, Y. et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics 29, 1971-1984 (2009).
52. Marx, R. E., Sawatari, Y, Fortin, M. & Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63, 1567-1575 (2005).
53. Treister, N. et al. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis. 15, 88-92 (2009).
54. Migliorati, C A., Hsu, C J., Chopra, S. & Kaltman, S. S. Dental management of patients with a history of bisphosphonate therapy: clinical dilemma. J. Calif. Dent. Assoc. 36, 769-774 (2008).
55. Takaishi, Y, Ikeo, T, Nakajima, M., Miki, T & Fujita, T A pilot case-control study on the alveolar bone density measurement in risk assessment for bisphosphonate-related osteonecrosis of the jaw. Osteoporos. Int 21, 815-825 (2009).
56. Stockmann, P et al. Panoramic radiograph, computed tomography or magnetic resonance maging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin. Oral Investig. 14, 311-317 (2009).
57. Bianchi, S. D., Scoletta, M., Cassione, F B., Migliaretti, G. & Mozzati, M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 104, 249-258 (2007).
58. Treister, N. S., Friedland, B. & Woo, S. B. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109, 753-764 (2010).
59. Bamias, A. et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: ncidence and risk factors. J. Clin. Oncol. 23, 8580-8587 (2005).
60. Durie, B. G., Katz, M. & Crowley, J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353, 99-102 (2005).
61. Zervas, K. et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br. J. Haematol. 134, 620-623 (2006).
62. Dimopoulos, M. A. et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91, 968-971 (2006).
63. Wang, E. P, Kaban, L. B., Strewler, G. J., Raje, N. & Troulis, M. J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J. Oral Maxillofac. Surg. 65, 1328-1331 (2007).
64. Walter, C, Grötz, K. A., Kunkel, M. & Al-Nawas, B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15, 197-202 (2007).
65. Walter, C et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur. Urol. 54, 1066-1072 (2008).
66. Boonyapakorn, T, Schirmer, I., Reichart, P A., Sturm, I. & Massenkeil, G. Bisphosphonate-nduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44, 857-869 (2008).
67. Walter, C et al. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115, 1631-1637 (2009).
68. Edwards, B. J. et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 9, 1166-1172 (2008).
69. Vahtsevanos, K. et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol. 27, 5356-5362 (2009).
70. Clarke, B. M. et al. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngol. Head Neck Surg. 136, 396-400 (2007).
71. Stumpe, M. R., Chandra, R. K., Yunus, F. & Samant, S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 31, 202-206 (2009).
72. Lo, J. C et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J. Oral Maxillofac. Surg. 68, 243-253 (2010).
73. Migliorati, C A. et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18, 1099-1106 (2010).
74. Reid, I. R., Bolland, M. J. & Grey, A. B. Is bisphosphonate- associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41, 318-320 (2007).
75. Reid, I. R. Osteonecrosis of the jaw: who gets it, and why? Bone 44, 4-10 (2009).
76. Allen, M. R. & Burr, D. B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J. Oral Maxillofac. Surg. 67 (Suppl.), 61-70 (2009).
77. Kumar, S. K. et al. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy Curr. Osteoporos. Rep. 8, 40-48 (2010).
78. Hoefert, S., Schmitz, I., Tannapfel, A. & Eufinger, H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin. Oral Investig. 14, 271-284 (2009).
79. Favia, G., Pilolli, G. P & Maiorano, E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45, 406-413 (2009).
80. Van den Wyngaert, T, Huizing, M. T, Fossion, E. & Vermorken, J. B. Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid. Oral Oncol. 46, 214-218 (2010).
81. Pozzi, S. et al. High-dose zoledronic acid mpacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin. Cancer Res. 15, 5829-5839 (2009).
82. Allen, M. R. & Burr, D. B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J. Oral Maxillofac. Surg. 66, 987-994 (2008).
83. Nastro, E. et al. Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonates. J. Oral Maxillofac. Surg. 67, 2701-2703 (2009).
84. Chen, H. et al. A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay Int. J. Oncol. 37, 71-79 (2010).
85. Lesclous, P et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of nflammation? Bone 45, 843-852 (2009).
86. Otto, S. et al. Bisphosphonate-related osteonecrosis of the jaw: Is pH the missing part in the pathogenesis puzzle? J. Oral Maxillofac. Surg. 68, 1158-1161 (2010).
87. Marx, R. E. Uncovering the cause of "phossy jaw" circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed. J. Oral Maxillofac. Surg. 66, 2356-2363 (2008).
88. Scheper, M. A., Badros, A., Chaisuparat, R., Cullen, K. J. & Meiller, T F. effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br. J. Haematol. 144, 667-676 (2009).
89. Sedghizadeh, P P. et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J. Am. Dent. Assoc 140, 1259-1265 (2009).
90. Naik, N. H. & Russo, T A. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin. Infect Dis. 49, 1729-1732 (2009).
91. Kikuiri, T. et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J. Bone Miner. Res. 25, 1668-1679 (2010).
92. Abu-Id, M. H. et al. "Bis-phossy jaws"\high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J. Craniomaxillofac. Surg. 36, 95-103 (2008).
93. Migliorati, C A., Schubert, M. M. & Peterson, D. E. Bisphosphonate osteonecrosis (BON): unanswered questions and research possibilities. Rev. Recent Clin. Trials 4, 99-109 (2009).
94. Ardine, M. et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann. Oncol. 17, 1336-1337 (2006).
95. Hokugo, A. et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J. Bone Miner. Res. 25, 1337-1349 (2010).
96. Migliorati, C A. et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J. Am. Dent. Assoc 136, 1658-1668 (2005).
97. Marx, R. E. Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 67 (Suppl.), 107-119 (2009).
98. Markose, G., Mackenzie, F. R., Currie, W. J. & Hislop, W. S. Bisphosphonate osteonecrosis: a protocol for surgical management. Br. J. Oral Maxillofac. Surg. 47, 294-297 (2009).
99. Pautke, C et al. Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy. J. Oral Maxillofac. Surg. 68, 125-129 (2010).
100. Tirelli, G. et al. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck 31, 1249-1254 (2009).
101. Stanton, D. C & Balasanian, E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J. Oral Maxillofac. Surg. 67, 943-950 (2009).
102. Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J. & Engroff, S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62, 527-534 (2004).
103. Freiberger, J. J. et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J. Oral Maxillofac. Surg. 65, 1321-1327 (2007).
104. Ruggiero, S. L., Fantasia, J. & Carlson, E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 102, 433-441 (2006).
105. Wutzl, A. et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30, 1224-1230 (2008).
106. Badros, A. et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol. 26, 5904-5909 (2008).
107. Estilo, C L. et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13, 911-920 (2008).
108. Vescovi, P et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed. Laser Surg. 26, 37-46 (2008).
109. Carlson, E. R. & Basile, J. D. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 67 (Suppl.), 85-95 (2009).
110. Saussez, S. et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 119, 323-329 (2009).
111. Stübinger, S. et al. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with er:YAG laser ablation. Lasers Surg. Med. 41, 26-30 (2009).
112. Junquera, L., Gallego, L., Cuesta, P, Pelaz, A. & de vicente, J. C Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. Am. J. Otolaryngol. 30, 390-395 (2009).
113. Chiu, C T, Chiang, W. F, Chuang, C Y & Chang, S. W. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw-a serial case analysis. J. Oral Maxillofac. Surg. 68, 1055-1063 (2010).
114. Stockmann, P et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 18, 449-460 (2010).
115. Williamson, R. A. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J. Oral Maxillofac. Surg. 39, 251-255 (2010).
116. Groetz, K. A. & Al-Nawas, B. Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J. Oral Maxillofac. Surg. 64, 1571-1572 (2006).
117. Fleisher, K. E. et al. Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: a technical note. J. Oral Maxillofac. Surg. 66, 2646-2653 (2008).
118. Angiero, F et al. Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the er:YAG laser. Lasers Med. Sci. 24, 849-856 (2009).
119. Vescovi, P et al. Surgical approach with er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers Med. Sci. 25, 101-113 (2010).
120. Yamaguchi, K. et al. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. J. Oral Maxillofac. Surg. 68, 889-897 (2010).
121. McLeod, N. M., Patel, V., Kusanale, A., Rogers, S. N. & Brennan, P A. Bisphosphosnate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br. J. Oral Maxillofac Surg. doi:10.1016/j.bjoms.2010.08.005.